Related Experiment Video
Updated: Jan 13, 2026
07:55
Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
Published on: April 11, 2018
14.9K
Primary Intracranial Alveolar Soft Part Sarcoma: Systematic Review
Haseeb Mehmood Qadri1, Hasan Saeed2, Muhammad Awais Ahmad3
1Haseeb Mehmood Qadri, MBBS. Punjab Institute of Neurosciences, Lahore, Pakistan.
Pakistan Journal of Medical Sciences
|January 12, 2026
Summary
Primary intracranial alveolar soft part sarcoma is rare. Surgical resection is the main treatment, with Transcription Factor E3 aiding diagnosis. Long-term monitoring is crucial for this slow-growing brain tumor.
Area of Science:
- Neuro-oncology
- Rare tumors
- Surgical pathology
Background:
- Alveolar soft part sarcoma (ASPS) is a rare malignancy with unknown origins.
- Primary intracranial ASPS is exceptionally uncommon.
- Understanding its clinical course and management is vital.
Purpose of the Study:
- To systematically review primary intracranial alveolar soft part sarcoma.
- To analyze clinical manifestations, progression, and treatment strategies.
Main Methods:
- Systematic review of PubMed, Google Scholar, and ScienceDirect (2000-2024).
- Included 18 cases from reports and series.
- Data extracted on presentation, imaging, pathology, and outcomes.
Main Results:
- Predominantly affected females (61.1%) with a mean age of 23.3 years.
- Common symptoms included headache (50%) and papilledema (33.3%).
- Frontal lobe was the most frequent site (33.3%); gross total resection achieved in 77.8%.
Conclusions:
- Surgical resection is the primary treatment modality.
- Transcription Factor E3 immunopositivity supports diagnosis.
- Long-term surveillance is necessary due to the indolent nature of the tumor.
